Differential genomic profiling of progesterone receptor (PR) negative, estrogen receptor (ER) positive HER2-negative metastatic breast cancer (MBC) through circulating tumor DNA

被引：0
|
作者：
Gerratana, Lorenzo
Davis, Andrew
Medford, Arielle
Reduzzi, Carolina
Clifton, Katherine
Podany, Emily
Hensing, Whitney
Velimirovic, Marko
Shah, Ami N.
Foffano, Lorenzo
Arcos, Laura Munoz
Nicolo, Eleonora
Dai, Charles S.
Keenan, Jennifer
Behdad, Amir
Wander, Seth
Gradishar, William
Ma, Cynthia
Puglisi, Fabio
Bardia, Aditya
Cristofanilli, Massimo
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-15-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-15-04
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?
    Gerratana, Lorenzo
    Davis, Andrew A.
    Foffano, Lorenzo
    Reduzzi, Carolina
    Podany, Emily L.
    Medford, Arielle J.
    Clifton, Katherine
    Velimirovic, Marko
    Putur, Annika
    Munoz-Arcos, Laura Sofia
    Pontolillo, Letizia
    Tapiavala, Shaili
    Molteni, Elisabetta
    Nicolo, Eleonora
    Gradishar, William John
    Ma, Cynthia X.
    Andreopoulou, Eleni
    Puglisi, Fabio
    Bardia, Aditya
    Cristofanilli, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [3] Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
    Liu, Xi-Yu
    Ma, Ding
    Xu, Xiao-En
    Jin, Xi
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    THERANOSTICS, 2018, 8 (22): : 6386 - 6399
  • [4] Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer
    Kubo, Makoto
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [5] Immunophenotype of estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative breast carcinomas
    Vladika, Natalia
    Anestakis, Doxakis
    Xirou, Persefoni
    Chatzinikolaou, Fotios
    Gianna, Kalliopi
    Patakiouta, Frideriki
    VIRCHOWS ARCHIV, 2007, 451 (02) : 200 - 200
  • [6] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [7] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Hao, Shuang
    Shao, Zhi-Ming
    BMC MEDICINE, 2015, 13
  • [8] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Ke-Da Yu
    Yi-Zhou Jiang
    Shuang Hao
    Zhi-Ming Shao
    BMC Medicine, 13
  • [9] Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer
    Darrigues, L.
    Pierga, J-Y
    Bernard, A.
    Bieche, I.
    Silveira, A.
    Michel, M.
    Sablin, M-P
    Cottu, P.
    Dubot, C.
    Geiss, R.
    Ricci, F.
    Proudhon, C.
    Bidard, F-C
    CANCER RESEARCH, 2019, 79 (04)
  • [10] The Evolving Use of SERDs in Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Jeselsohn, Rinath M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 428 - 431
12345